JP2016516791A5 - - Google Patents

Download PDF

Info

Publication number
JP2016516791A5
JP2016516791A5 JP2016508109A JP2016508109A JP2016516791A5 JP 2016516791 A5 JP2016516791 A5 JP 2016516791A5 JP 2016508109 A JP2016508109 A JP 2016508109A JP 2016508109 A JP2016508109 A JP 2016508109A JP 2016516791 A5 JP2016516791 A5 JP 2016516791A5
Authority
JP
Japan
Prior art keywords
pyrrolo
pyridine
carbonitrile
amino
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016508109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016516791A (ja
JP6461097B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/057482 external-priority patent/WO2014170248A1/en
Publication of JP2016516791A publication Critical patent/JP2016516791A/ja
Publication of JP2016516791A5 publication Critical patent/JP2016516791A5/ja
Application granted granted Critical
Publication of JP6461097B2 publication Critical patent/JP6461097B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016508109A 2013-04-18 2014-04-14 Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物 Expired - Fee Related JP6461097B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201300231 2013-04-18
DKPA201300231 2013-04-18
PCT/EP2014/057482 WO2014170248A1 (en) 2013-04-18 2014-04-14 Arylpyrrolopyridine derived compounds as lrrk2 inhibitors

Publications (3)

Publication Number Publication Date
JP2016516791A JP2016516791A (ja) 2016-06-09
JP2016516791A5 true JP2016516791A5 (https=) 2018-08-09
JP6461097B2 JP6461097B2 (ja) 2019-01-30

Family

ID=59093654

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016508109A Expired - Fee Related JP6461097B2 (ja) 2013-04-18 2014-04-14 Ｌｒｒｋ２阻害剤としてのアリールピロロピリジン誘導化合物

Country Status (8)

Country Link
US (3) US9499542B2 (https=)
EP (1) EP2986608B1 (https=)
JP (1) JP6461097B2 (https=)
CN (1) CN105263930B (https=)
AR (1) AR095885A1 (https=)
ES (1) ES2642204T3 (https=)
TW (1) TW201533043A (https=)
WO (1) WO2014170248A1 (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
SMT202100699T1 (it) 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
JOP20190126A1 (ar) * 2016-12-22 2019-05-28 H Lundbeck As بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1
KR101923852B1 (ko) * 2017-02-24 2018-11-29 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
CN110662745B (zh) * 2017-03-23 2021-08-03 大邱庆北尖端医疗产业振兴财团 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
AU2018381574B2 (en) * 2017-12-05 2022-09-15 Oscotec Inc. Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
EP3723807B1 (en) 2017-12-14 2021-10-20 H. Lundbeck A/S Combination treatments comprising administration of 1h-pyrazolo[4,3-b]pyridines
WO2019121840A1 (en) 2017-12-20 2019-06-27 H. Lundbeck A/S Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors
TW202012410A (zh) * 2018-07-23 2020-04-01 美國商拜爾布拉克斯股份有限公司 激酶拮抗劑及其製備和使用方法
KR101990739B1 (ko) * 2018-07-24 2019-06-19 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR101992059B1 (ko) * 2018-08-23 2019-06-21 재단법인 대구경북첨단의료산업진흥재단 혈액 뇌관문을 통과할 수 있는 화합물을 유효성분으로 함유하는 뇌암의 예방 또는 치료용 약학적 조성물
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
KR102133595B1 (ko) * 2019-05-31 2020-07-13 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
EP4238975A4 (en) * 2020-10-29 2024-06-12 Suzhou Yabao Pharmaceutical R&D Co., Ltd. SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
CN112852954A (zh) * 2021-03-16 2021-05-28 江苏贝格尔生物医药有限公司 一种检测lrrk2基因1628多态性的引物和探针及试剂盒
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
US20250361230A1 (en) * 2022-06-06 2025-11-27 The USA, as Represented by the Secretary, Dept. of Heath and Human Services LATS Inhibitors and Uses Thereof
CN119707961B (zh) * 2024-12-02 2025-10-24 重庆飞因科生物科技有限公司 吡啶并吡咯类氨基酸衍生物及其在制备富亮氨酸重复激酶2抑制剂中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612086B2 (en) * 2003-05-16 2009-11-03 Eisai R & D Management Co. Ltd. JNK inhibitors
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
WO2007084667A2 (en) * 2006-01-19 2007-07-26 Osi Pharmaceutical, Inc. Fused heterobicyclic kinase inhibitors
EP1981887A2 (en) * 2006-02-01 2008-10-22 SmithKline Beecham Corporation Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors
GB0617161D0 (en) * 2006-08-31 2006-10-11 Vernalis R&D Ltd Enzyme inhibitors
WO2008110508A1 (en) * 2007-03-09 2008-09-18 Glaxo Group Limited Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity
KR101313804B1 (ko) 2007-03-20 2013-10-01 쿠리스 인코퍼레이션 Ｈｓｐ９０ 억제제로서의 융합된 아미노 피리딘
EP2408772B1 (en) * 2009-03-19 2015-07-01 Medical Research Council Technology Compounds
GB201008134D0 (en) * 2010-05-14 2010-06-30 Medical Res Council Technology Compounds
GB201015949D0 (en) 2010-09-22 2010-11-03 Medical Res Council Technology Compounds
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
TW201533043A (zh) 2013-04-18 2015-09-01 Lundbeck & Co As H 作爲ｌｒｒｋ２抑制劑的芳基吡咯并吡啶衍生化合物

Similar Documents

Publication Publication Date Title
JP2016516791A5 (https=)
JP2018532788A5 (https=)
JP2011503230A5 (https=)
JP2016525076A5 (https=)
JP2017504652A5 (https=)
MX2010012290A (es) Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
JP2018519323A5 (https=)
RU2009142851A (ru) Ингибиторы киназы, пригодные для лечения миелопролиферативных заболеваний и других пролиферативных заболеваний
JP2021501145A5 (https=)
HRP20220990T1 (hr) 3-supstituirane propionske kiseline kao inhibitori alfa v integrina
JP2020512343A5 (https=)
RU2010125220A (ru) Ненуклеозидные ингибиторы обратной транскриптазы
JP2016522232A5 (https=)
IL292608A (en) History of pyridine-2(1h)-one quinolinone as mutant dehydrogenase inhibitors-isocitrate
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
RU2016141645A (ru) ИНГИБИТОРЫ TrkA КИНАЗЫ, ОСНОВАННЫЕ НА НИХ КОМПОЗИЦИИ И СПОСОБЫ
RU2011114487A (ru) Гетероциклические соединения как ингибиторы протеинкиназы
JP2017519836A5 (https=)
RU2017116196A (ru) 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1
RU2017120217A (ru) 2-амино-5,5-дифтор-6-(фторметил)-6-фенил-3,4,5,6-тетрагидпропиридины в качестве ингибиторов bace1
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
JP2020503302A5 (https=)
RU2018102087A (ru) Производное 1,4-дизамещенного имидазола
RU2012120901A (ru) Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r
JP2013523814A5 (https=)